Vigil Neuroscience Inc
VIGL8.055USD
+0.005+0.06%
交易中 （美東）報價延遲15分鐘
375.94M總市值
虧損本益比TTM
關於 Vigil Neuroscience Inc 公司
Vigil Neuroscience, Inc. 是一家臨牀階段的生物技術公司。該公司專注於通過恢復小膠質細胞（大腦的哨兵免疫細胞）的警覺性來開發罕見和常見神經退行性疾病的治療方法。該公司正在利用現代神經科學藥物開發工具，在多種治療方式中努力開發精準療法，以改善患者及其家人的生活。其主要臨牀候選藥物 VGL101 (iluzanebart) 是一種完全人源單克隆抗體 TREM2 激動劑，目前正在對患有軸突球體和色素膠質細胞的成人發病性白質腦病患者進行 2 期概念驗證試驗。該公司還在開發 VG-3927，這是其口服小分子 TREM2 激動劑計劃，用於治療與小膠質細胞功能障礙相關的常見神經退行性疾病，最初的重點是基因定義的亞羣中的阿爾茨海默病。
公司簡介
公司代碼VIGL
公司名稱Vigil Neuroscience Inc
上市日期Jan 07, 2022
CEODr. Ivana Magovcevic-Liebisch, J.D., Ph.D.
員工數量69
證券類型Ordinary Share
年結日Jan 07
公司地址100 Forge Road
城市WATERTOWN
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編02472
電話18572544445
網址https://www.vigilneuro.com/
公司代碼VIGL
上市日期Jan 07, 2022
CEODr. Ivana Magovcevic-Liebisch, J.D., Ph.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Samantha Budd Haeberlein, Ph.D.
Dr. Samantha Budd Haeberlein, Ph.D.
Independent Director
Independent Director
--
--
Dr. Bruce L. Booth
Dr. Bruce L. Booth
Independent Chairman of the Board
Independent Chairman of the Board
--
-100.00%
Dr. Cheryl Renee Blanchard, Ph.D.
Dr. Cheryl Renee Blanchard, Ph.D.
Independent Director
Independent Director
--
--
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Independent Director
Independent Director
--
-100.00%
Dr. Ivana Magovcevic-Liebisch, J.D., Ph.D.
Dr. Ivana Magovcevic-Liebisch, J.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Petra Kaufmann, M.D.
Ms. Petra Kaufmann, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. David Gray, Ph.D.
Dr. David Gray, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Gerhard Koenig, Ph.D.
Dr. Gerhard Koenig, Ph.D.
Independent Director
Independent Director
--
--
Ms. Jennifer Ziolkowski, CPA
Ms. Jennifer Ziolkowski, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Stefan Vitorovic
Mr. Stefan Vitorovic
Independent Director
Independent Director
--
-100.00%
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Samantha Budd Haeberlein, Ph.D.
Dr. Samantha Budd Haeberlein, Ph.D.
Independent Director
Independent Director
--
--
Dr. Bruce L. Booth
Dr. Bruce L. Booth
Independent Chairman of the Board
Independent Chairman of the Board
--
-100.00%
Dr. Cheryl Renee Blanchard, Ph.D.
Dr. Cheryl Renee Blanchard, Ph.D.
Independent Director
Independent Director
--
--
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Independent Director
Independent Director
--
-100.00%
Dr. Ivana Magovcevic-Liebisch, J.D., Ph.D.
Dr. Ivana Magovcevic-Liebisch, J.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Petra Kaufmann, M.D.
Ms. Petra Kaufmann, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 8月1日 週五
更新時間: 8月1日 週五
持股股東
股東類型
持股股東
持股股東
佔比
Atlas Venture
12.51%
Beryl Capital Management, LLC
9.87%
BVF Partners L.P.
8.60%
Amgen Inc
6.87%
Glazer Capital, LLC
5.39%
Other
56.77%
持股股東
持股股東
佔比
Atlas Venture
12.51%
Beryl Capital Management, LLC
9.87%
BVF Partners L.P.
8.60%
Amgen Inc
6.87%
Glazer Capital, LLC
5.39%
Other
56.77%
股東類型
持股股東
佔比
Hedge Fund
33.86%
Venture Capital
17.21%
Investment Advisor
11.63%
Corporation
6.87%
Investment Advisor/Hedge Fund
3.73%
Individual Investor
0.51%
Research Firm
0.40%
Bank and Trust
0.17%
Other
25.62%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
167
34.72M
74.40%
-8.46M
2025Q1
155
37.71M
83.92%
-8.48M
2024Q4
145
40.31M
98.61%
+1.04M
2024Q3
142
37.92M
96.31%
-1.37M
2024Q2
139
36.35M
96.29%
-1.95M
2024Q1
131
36.78M
100.64%
+157.59K
2023Q4
124
35.04M
97.83%
-1.22M
2023Q3
117
35.82M
100.15%
-590.79K
2023Q2
111
36.00M
101.04%
+568.49K
2023Q1
103
35.28M
105.30%
-113.43K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Atlas Venture
5.84M
12.51%
--
--
Jun 11, 2025
Beryl Capital Management, LLC
4.61M
9.87%
+4.61M
--
May 22, 2025
BVF Partners L.P.
4.01M
8.6%
+2.20M
+121.30%
Mar 31, 2025
Amgen Inc
3.21M
6.87%
--
--
Jun 11, 2025
Glazer Capital, LLC
2.51M
5.39%
+2.51M
--
May 28, 2025
Invus Public Equities Advisors, LLC
1.97M
4.21%
-23.97K
-1.20%
Mar 31, 2025
683 Capital Management LLC
1.74M
3.73%
+340.00K
+24.29%
Mar 31, 2025
VV Manager LLC
1.63M
3.5%
-3.38M
-67.41%
Jun 11, 2025
Sphera Funds Management Ltd.
1.60M
3.44%
+102.00K
+6.79%
Mar 31, 2025
Ensign Peak Advisors, Inc.
1.58M
3.38%
+875.00K
+124.45%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
NYLI Merger Arbitrage ETF
0.2%
iShares Health Innovation Active ETF
0.1%
iShares Micro-Cap ETF
0.05%
Avantis US Small Cap Equity ETF
0.01%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0%
Proshares Ultra Russell 2000
0%
iShares Russell 2000 Value ETF
0%
iShares Russell 2000 ETF
0%
Global X Russell 2000 ETF
0%
ProShares Hedge Replication ETF
0%
查看更多
NYLI Merger Arbitrage ETF
佔比0.2%
iShares Health Innovation Active ETF
佔比0.1%
iShares Micro-Cap ETF
佔比0.05%
Avantis US Small Cap Equity ETF
佔比0.01%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
佔比0%
Proshares Ultra Russell 2000
佔比0%
iShares Russell 2000 Value ETF
佔比0%
iShares Russell 2000 ETF
佔比0%
Global X Russell 2000 ETF
佔比0%
ProShares Hedge Replication ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
